INCOGNITO-SOFTWARE
14.3.2022 14:02:05 CET | Business Wire | Press release
Incognito Software Systems Inc. , a leading global provider of broadband service orchestration software solutions for digital service providers, announces that Optima Italia S.p.A. has gone live with Incognito’s Digital Experience (DX) Solution to streamline and improve the customer experience. With Incognito, Optima can centralize and streamline the management of all devices in its network to deliver an uninterrupted, high-quality customer experience using a carrier-grade solution that can scale with their network and service growth.
As a leading Italian digital company service provider, Optima offers an integrated collection of services, including electricity, gas, mobile, and Internet for business and residential markets. To support a significant and growing customer base across major centers, Optima required a solution to scale operations by replacing time- and labor-intensive manual processes with an industry awarded platform. Underpinned by Incognito’s fully featured Broadband Forum-compliant Auto Configuration Server (ACS) , the Digital Experience smart platform automates the resolution of technical issues that impact service quality.
Optima selected Incognito to support them in their automation efforts based on Incognito’s expertise enhancing subscriber experience, reducing operational costs, and supporting the delivery of innovative services into the connected home. “It was quickly apparent that Incognito could offer a great platform implementation, with system go-live in a matter of weeks,” said Paolo Primiani, Network & Voice engineer at Optima Italia.
“We are very proud to be working with Optima Italia as a technology partner for their rollout of high-speed fiber broadband services to customers across its service areas,” said Ricardo Gonzalez, VP of Sales at Incognito. “Optima is one of the leading broadband providers in Italy, respected for their dedication to customer experience. Our mission is to provide telecom operators with tools that help them increase efficiency while reducing costs, and we look forward to contributing to Optima’s success.”
The Digital Experience Solution (DX) is an industry awarded platform, used around the world by premier broadband service providers to manage and orchestrate internet of things (IoT) and customer premise equipment (CPE) with Broadband Forum’s TR-069, User Services Platform (USP / TR-369) , and other management protocols. To learn more about Digital Experience Solution and Incognito’s suite of orchestration solutions, visit www.incognito.com .
About Incognito
Incognito Software Systems Inc. provides service orchestration software and services that help digital service providers manage the next-generation broadband experience. Over 200 customers worldwide, including Claro, Cox, Digicel, Globe, and Orange, leverage Incognito solutions to fast-track the introduction of innovative broadband services over fiber, cable, and fixed wireless technologies, while delivering a great customer experience. The company is a division of the Lumine Group , a portfolio of Constellation Software Inc. , the largest independent software company in Canada. Visit www.incognito.com or follow us on LinkedIn and Twitter .
About Optima Italia
Optima Italia S.p.A., is a leading Italian digital company for the integrated provision of energy (electricity and gas) and telecommunications (internet, telephone, and mobile) services for the business and consumer markets. Optima was founded in 1999 by entrepreneurs Danilo Caruso and Alessio Matrone with the objective of creating a service company to simplify life for families and businesses. Visit www.optimaitalia.com , or follow on LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220314005117/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom